Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2024 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean timina i (22 results)?
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L, Wildner L, McHugh TD, Fuhr U, Aldana BH, Mouhdad C, Brake LT, Boeree MJ, Aarnoutse RE, Svensson EM, Gong X, P J Phillips P, Diacon AH, Hoelscher M; PanACEA-TB consortium. Heinrich N, et al. Lancet Microbe. 2025 Feb;6(2):100952. doi: 10.1016/j.lanmic.2024.07.015. Epub 2025 Jan 7. Lancet Microbe. 2025. PMID: 39793592 Free article. Clinical Trial.
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Koele SE, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2305-2313. doi: 10.1093/jac/dkaf210. J Antimicrob Chemother. 2025. PMID: 40613338 Free PMC article. Clinical Trial.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Noreña I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM; PanACEA consortium. Heinrich N, et al. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00213-0. doi: 10.1016/S1473-3099(25)00213-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645196 Free article.
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Minja LT, et al. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00289-0. doi: 10.1016/S1473-3099(25)00289-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645198 Free article.
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis.
De Castro N, Chazallon C, N'takpe JB, Timana I, Escada R, Wagner S, Messou E, Eholie S, Bhatt N, Khosa C, Laureillard D, Do Chau G, Veloso VG, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B, Marcy O; ANRS 12300 Reflate TB2 Study Group. De Castro N, et al. Among authors: timana i. Open Forum Infect Dis. 2022 Nov 19;9(12):ofac628. doi: 10.1093/ofid/ofac628. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540390 Free PMC article.
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Coelho LE, Chazallon C, Laureillard D, Escada R, N'takpe JB, Timana I, Messou E, Eholie S, Khosa C, Chau GD, Cardoso SW, Veloso VG, Delaugerre C, Molina JM, Grinsztejn B, Marcy O, De Castro N. Coelho LE, et al. Among authors: timana i. Open Forum Infect Dis. 2024 Jan 22;11(3):ofae035. doi: 10.1093/ofid/ofae035. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38486816 Free PMC article. Clinical Trial.
Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis - a secondary analysis of the ANRS 12300 Reflate TB2 trial.
Akpata R, Ntakpe JB, Messou E, De Castro N, Chazallon C, Timana I, Escada R, Cardoso SW, Bhatt N, Khosa C, Laureillard D, Do Chau G, Nogbou FE, Glao DD, Veloso V, Molina JM, Grinsztejn B, Zannou M, Eholie S, Marcy O; ANRS 12300 Reflate TB2 study Consortium. Akpata R, et al. Among authors: timana i. BMC Infect Dis. 2025 May 14;25(1):695. doi: 10.1186/s12879-025-10986-4. BMC Infect Dis. 2025. PMID: 40361016 Free PMC article. Clinical Trial.